GO:0035375 zymogen binding: mechanism and genes

GO:0035375 zymogen binding is a molecular function that describes the binding of a protein or other molecule to a zymogen, which is an enzymatically inactive precursor of an enzyme that is often converted to an active enzyme by proteolysis. This function is essential for understanding how proteolytic cascades are controlled, because zymogens must be recognized, localized, and often stabilized before they are activated. For example, the binding of coagulation factor XIII zymogen to activated platelet subpopulations depends on integrin αIIbβ3 and fibrinogen, linking zymogen binding to platelet biology and clot formation. Similarly, the structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus shows how a host protease zymogen can be engaged by a viral protein, with implications for viral entry. Researchers study zymogen binding because it sits at the intersection of enzyme regulation, protein-protein recognition, and disease. In blood coagulation, the fragment 1 region of prothrombin facilitates the favored binding of fragment 12 to zymogen and enforces zymogen-like character in the proteinase, illustrating how binding events can tune enzymatic activity. In apoptosis, the crystal structure of a procaspase-7 zymogen revealed mechanisms of activation and substrate binding, showing that zymogen recognition is part of the apoptotic switch. In malaria, structures of plasmepsin X from Plasmodium falciparum revealed a novel inactivation mechanism of the zymogen and the molecular basis for inhibitor binding in the mature enzyme, connecting zymogen binding to antiparasitic drug design. Because zymogen binding is a molecular function rather than a single pathway, it is studied across many systems, from thrombin and its zymogen-like states to caspase denitrosylation and conformational selection during zymogen activation [3,7,8]. This article summarizes the definition, mechanisms, key genes, disease links, and research methods for GO:0035375, with an emphasis on how CRISPR-based cell models can be used to test causal roles of zymogen-binding proteins.

In simple terms, zymogen binding means a molecule attaches to an inactive enzyme precursor. The official GO definition states: Binding to a zymogen, an enzymatically inactive precursor of an enzyme that is often convertible to an active enzyme by proteolysis. This function is annotated as a molecular_function and includes the synonym proenzyme binding. It does not describe the proteolytic activation event itself, but rather the recognition and binding interaction with the zymogen form.

Zymogen binding is important because it controls when and where powerful enzymes become active. Many enzymes are synthesized as inactive zymogens to prevent unwanted proteolysis, and binding interactions with zymogens can localize them to specific surfaces, stabilize inactive conformations, or prime them for activation. For instance, the binding of coagulation factor XIII zymogen to activated platelet subpopulations through integrin αIIbβ3 and fibrinogen shows how zymogen binding is integrated into platelet function and hemostasis. Slow thrombin is zymogen-like, meaning that its binding properties and activity are influenced by zymogen-like states. The fragment 1 region of prothrombin facilitates favored binding of fragment 12 to zymogen and enforces zymogen-like character in the proteinase, demonstrating that zymogen binding can modulate enzymatic behavior. In infection, TMPRSS2 zymogen activation and recognition by HKU1 coronavirus highlights how pathogen proteins can exploit zymogen binding for entry. Therefore, understanding zymogen binding provides mechanistic insight into coagulation, apoptosis, infectious disease, and drug development.

The following genes and proteins are experimentally linked to zymogen binding or zymogen-like regulation in the cited literature.

Zymogen binding is regulated at multiple levels. Conformational selection can shift zymogens between inactive and activation-competent states, as shown in studies of zymogen activation. Binding to cofactors and surfaces, such as platelet integrins and fibrinogen, localizes zymogens and modulates their availability. Proteolytic processing converts zymogens to active enzymes, but binding interactions can stabilize zymogen-like conformations, as seen for slow thrombin and prothrombin fragment interactions [3,5]. Redox modifications such as denitrosylation can also influence caspase zymogen behavior. In infectious contexts, viral proteins can recognize host zymogens, as with TMPRSS2 and HKU1 coronavirus. Together, these mechanisms ensure that zymogen binding is tightly controlled in time and space.

Zymogen binding is directly relevant to thrombosis and hemostasis. Coagulation factor XIII zymogen binds to activated platelet subpopulations through integrin αIIbβ3 and fibrinogen, a process that contributes to clot stability. Thrombin can adopt zymogen-like states, and prothrombin fragment interactions enforce zymogen-like character, which can influence coagulation balance [3,5]. Dysregulation of these binding events may contribute to thrombotic or bleeding phenotypes, making them attractive for experimental modeling.

Zymogen binding can be exploited by viruses. The structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus demonstrates how a host protease zymogen is engaged during viral entry. This links zymogen binding to infectious disease and suggests that interfering with zymogen recognition could be a therapeutic strategy.

Procaspase-7 zymogen structure revealed mechanisms of activation and substrate binding, which are central to apoptosis. Fas-induced caspase denitrosylation further shows redox control of caspase activity. Because apoptosis evasion is a hallmark of cancer, zymogen binding and activation mechanisms in caspases are relevant to cancer biology and therapy.

Plasmepsin X from Plasmodium falciparum has a zymogen inactivation mechanism and is a target for inhibitors in the mature enzyme. This connects zymogen binding to malaria and antiparasitic drug development.

X-ray crystallography and cryo-EM have been used to determine structures of zymogens and their binding partners, such as procaspase-7 and plasmepsin X [4,6]. These methods reveal the molecular basis of zymogen recognition and inactivation.

Platelet binding assays and protein-protein interaction studies have been used to measure factor XIII zymogen binding to activated platelets. Such assays can be adapted to other zymogen systems.

CRISPR knockout, point mutation, and knock-in models allow causal testing of genes involved in zymogen binding. For example, knocking out TMPRSS2 or mutating its zymogen surface can test its role in viral recognition.

Proteomic profiling and bioinformatic analysis can identify zymogen-binding partners and pathways. These approaches complement structural and cell-based studies [4,8].

Researchers studying zymogen binding-related genes often need to determine whether a candidate gene is causally involved in zymogen recognition, activation, or disease. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses with publication-ready rigor.

GO:0035375 zymogen binding is a fundamental molecular function that governs how inactive enzyme precursors are recognized, localized, and stabilized. From coagulation factor XIII and thrombin to TMPRSS2, plasmepsin X, and procaspase-7, zymogen binding is embedded in hemostasis, infection, apoptosis, and parasitic disease [1,2,3,4,5,6]. Understanding its mechanisms can reveal therapeutic opportunities and guide experimental design. CRISPR-based cell models provide a direct way to test the causal roles of zymogen-binding proteins. By combining knockout, point mutation, knock-in, overexpression, and screening approaches, researchers can move from correlation to mechanism in zymogen binding biology.